Marco R. de Groot

2.1k total citations
28 papers, 1.1k citations indexed

About

Marco R. de Groot is a scholar working on Oncology, Hematology and Epidemiology. According to data from OpenAlex, Marco R. de Groot has authored 28 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 12 papers in Hematology and 7 papers in Epidemiology. Recurrent topics in Marco R. de Groot's work include Hematopoietic Stem Cell Transplantation (10 papers), Acute Myeloid Leukemia Research (6 papers) and Cancer Cells and Metastasis (6 papers). Marco R. de Groot is often cited by papers focused on Hematopoietic Stem Cell Transplantation (10 papers), Acute Myeloid Leukemia Research (6 papers) and Cancer Cells and Metastasis (6 papers). Marco R. de Groot collaborates with scholars based in Netherlands, France and Germany. Marco R. de Groot's co-authors include Leon W.M.M. Terstappen, W. J. B. Mastboom, Arjan G.J. Tibbe, I. Vermes, Bas Franken, Jean‐Yves Pierga, François‐Clément Bidard, Job van der Palen, Tanja Fehm and Carolyn Hall and has published in prestigious journals such as Blood, PLoS ONE and Cancer.

In The Last Decade

Marco R. de Groot

27 papers receiving 1.1k citations

Peers

Countries citing papers authored by Marco R. de Groot

Since Specialization

Citations

This map shows the geographic impact of Marco R. de Groot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco R. de Groot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco R. de Groot more than expected).

Fields of papers citing papers by Marco R. de Groot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco R. de Groot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco R. de Groot. The network helps show where Marco R. de Groot may publish in the future.

Co-authorship network of co-authors of Marco R. de Groot

This figure shows the co-authorship network connecting the top 25 collaborators of Marco R. de Groot. A scholar is included among the top collaborators of Marco R. de Groot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco R. de Groot. Marco R. de Groot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Beneficial effect of PTCy and a short duration of immune suppression on relapse risk in acute myeloid leukemia patients with pretransplant MRD 2025 ·Bone Marrow Transplantation ·Linde M. Morsink, (unknown), (unknown), Goda Choi, Marco R. de Groot, Emanuele Ammatuna, Saskia K. Klein, Carolien M. Woolthuis, (unknown), (unknown), Laura Bungener, Kees Meijer, André B. Mulder, Gerwin Huls	0
2	Improved Outcome of Allogeneic Transplantation in Older Patients Treated for Myeloid Malignancies Using Post-Transplantation Cyclophosphamide and Reduced Duration of Immune Suppression 2024 ·Transplantation and Cellular Therapy ·Linde M. Morsink, (unknown), Goda Choi, Marco R. de Groot, (unknown), Mar Bellido, (unknown), Laura Bungener, Kees Meijer, André B. Mulder, Gerwin Huls	4
3	Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study 2022 ·Blood Advances ·(unknown), Aniek O. de Graaf, René Mulder, Laura Bungener, (unknown), André B. Mulder, Goda Choi, Jan Jacob Schuringa, Marco R. de Groot, Edo Vellenga, Joop H. Jansen, Gerwin Huls, Isabelle A. van Zeventer	5
4	Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation 2021 ·Bone Marrow Transplantation ·(unknown), (unknown), Walter J. F. M. van der Velden, Joop H. Jansen, Brigitte Bär, Nicolaas Schaap, (unknown), André B. Mulder, Marco R. de Groot, Frédéric Baron, Edo Vellenga, (unknown), Gerwin Huls	7
5	Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis 2021 ·Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin ·(unknown), Gürsah Kats‐Ugurlu, Remco J. Renken, Henk J. Buikema, Marco R. de Groot, Marijn C. Visschedijk, Gerard Dijkstra, Mathilde Jalving, Jacco J. de Haan	16
6	Exploratory Study of Predicted Indirectly ReCognizable HLA Epitopes in Mismatched Hematopoietic Cell Transplantations 2019 ·Frontiers in Immunology ·Kirsten Geneugelijk, (unknown), Hanneke W. M. van Deutekom, Jorg J. A. Calis, (unknown), Can Keşmir, Machteld Oudshoorn, Bronno van der Holt, Ellen Meijer, Sacha Zeerleder, Marco R. de Groot, Peter A. von dem Borne, Nicolaas Schaap, Jan J. Cornelissen, Jürgen Kuball, Eric Spierings	14
7	Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen 2018 ·Clinical Cancer Research ·(unknown), Myriam Labopin, Annalisa Ruggeri, Jan J. Cornelissen, Ellen Meijer, Henrik Sengeloev, Dietger Niederwieser, Marco R. de Groot, Harry C. Schouten, Nöel Milpied, Didier Blaise, Bipin N. Savani, Éliane Gluckman, Mohamad Mohty, Arnon Nagler	31
8	Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer 2016 ·Clinical Cancer Research ·Wolfgang Janni, Brigitte Rack, Leon W.M.M. Terstappen, Jean‐Yves Pierga, Florin‐Andrei Taran, Tanja Fehm, Carolyn Hall, Marco R. de Groot, François‐Clément Bidard, Thomas W. P. Friedl, Peter A. Fasching, Sara Y. Brucker, Klaus Pantel, Anthony Lucci	265
9	Importance of circulating tumor cells in newly diagnosed colorectal cancer 2015 ·International Journal of Oncology ·Guus van Dalum, (unknown), (unknown), W. J. B. Mastboom, I. Vermes, Arjan G.J. Tibbe, Marco R. de Groot, Leon W.M.M. Terstappen	91
10	Circulating tumor cells before and during follow-up after breast cancer surgery 2014 ·International Journal of Oncology ·Guus van Dalum, (unknown), Arjan G.J. Tibbe, Bas Franken, W. J. B. Mastboom, (unknown), Marco R. de Groot, Leon W.M.M. Terstappen	52
11	Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer 2013 ·PLoS ONE ·Sjoerd T. Ligthart, Frank Coumans, François‐Clément Bidard, Lieke H. J. Simkens, Cornelis J.A. Punt, Marco R. de Groot, Gerhardt Attard, Johann S. de Bono, Jean‐Yves Pierga, Leon W.M.M. Terstappen	76
12	Abstract PD6-6: A pooled analysis of the prognostic relevance of circulating tumor cells in early breast cancer 2013 ·Cancer Research ·(unknown), (unknown), (unknown), J-Y Pierga, Tanja Fehm, Carolyn Hall, Marco R. de Groot, (unknown), F Meier-Stiegen, Thomas W. P. Friedl, Peter A. Fasching, Anthony Lucci	9
13	A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell carcinoma 2009 ·Cancer ·Christian Wülfing, Jean‐Pascal Machiels, D. J. Richel, Marc‐Oliver Grimm, Uwe Treiber, Marco R. de Groot, Philippe Beuzeboc, Roma Parikh, Frank Pétavy, Iman El‐Hariry	172
14	Vaccination responses and lymphocyte subsets after autologous stem cell transplantation 2007 ·Vaccine ·Ankie M.T. van der Velden, A.M.E. Claessen, Heleen van Velzen‐Blad, Marco R. de Groot, Mark H.H. Kramer, Douwe H. Biesma, Ger T. Rijkers	20
15	Can causes of false-normal D-dimer test [SimpliRED®] results be identified? 2003 ·Thrombosis Research ·Roderik A. Kraaijenhagen, (unknown), Maria M.W. Koopman, Marco R. de Groot, Franco Piovella, Paolo Prandoni, Harry R. Büller	13
16	HIV infection in critically ill obstetrical patients 2003 ·International Journal of Gynecology & Obstetrics ·Marco R. de Groot, (unknown), H. S. Cronjé, G Joubert	13
17	Changes in perfusion scintigraphy in the first days of heparin therapy in patients with acute pulmonary embolism 2000 ·European Journal of Nuclear Medicine and Molecular Imaging ·Marco R. de Groot, Ad H. Oostdijk, (unknown), Marinus van Marwijk Kooy, Harry R. Büller	8
18	Toxin‐mediated haemolytic uraemic syndrome without diarrhoea 2000 ·Journal of Internal Medicine ·Arnon P. Kater, Anneke M. Westermann, Marco R. de Groot, A. E. G. Kr. von dem Borne, Ed J. Kuijper	6
19	Identification of Two Distinct Mutations at the Same Nucleotide Position, Concomitantly with a Novel Polymorphism in the Vasopressin-Neurophysin II Gene (AVP-NP II) in Two Dutch Families with Familial Neurohypophyseal Diabetes Insipidus 2000 ·Clinical Chemistry ·(unknown), (unknown), Erica L T van den Akker, Marco R. de Groot, Anton Franken, (unknown), Henk Engel	18
20	Non invasive ultrasound measurement of intima-media thickness. A tool to measure early atherosclerosis 1994 ·European Journal of Vascular Surgery ·Marco R. de Groot, Jan Dirk Banga	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact